Subscribe Become an Author Add Company Sign Up Log In



Private company

BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform.

This platform combines patient biology and artificial intelligence-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems.

Private company
United States of America based
$1.300 M
Research papers
Business model
  • Own Drug Discovery Programs
  • Software as a Service / AI as Service (SaaS, AIaaS)
Therapeutic focus
  • Cardiovascular
  • Endocrine
  • Oncology
  • Rare Diseases
Data type used for modelling
  • EHRs/lab notebooks/databases (structured data mining)
  • HTS and HCS data
  • Network biology analysis (omics)
Drug Discovery Strategy
  • Network Analysis, Omics Approach
  • Phenotypic Drug Discovery (PDD)
Research focus
  • Data mining / Ontology building
  • Lead Discovery

Investing history

2010Unknown Round1.3

Press releases

    No mentions found

Posts Mentioning This Company

Biopharma Insights
Drug Discovery Insights


No products posted yet


No services posted yet

Clinical Trials

    No patents found

Publications (PubMed)
  • 31486672 (from 2019-09-06), bAIcis: A Novel Bayesian Network Structural Learning Algorithm and Its Comprehensive Performance Evaluation Against Open-Source Software.
  • 29861389 (from 2018-06-05), Cardiolipin Synthesis in Brown and Beige Fat Mitochondria Is Essential for Systemic Energy Homeostasis.
  • 29580805 (from 2018-03-28), Mycoplasma infection and hypoxia initiate succinate accumulation and release in the VM-M3 cancer cells.
  • 28753864 (from 2017-07-30), Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.
  • 28178530 (from 2017-02-09), Lipidomic Adaptations in White and Brown Adipose Tissue in Response to Exercise Demonstrate Molecular Species-Specific Remodeling.

Assets (therapeutic products)

    No assets found

Year Partner Focus Amount of Deal

(2017, Jan. 1)
Sanofi assess potential biomarkers of seasonal influenza vaccination outcomes in an unbiased and data-driven manner. --

(2017, Jan. 1)
AstraZeneca The tie-up will focus on finding and evaluating novel ways of treating Parkinson's disease and other neurological disorders. --